Page 1434 - Clinical Small Animal Internal Medicine

1372 Section 11 Oncologic Disease

Plateletpheresis products could be considered for dogs with acute, life‐
VetBooks.ir Although, as stated previously, one of the primary uses of threatening bleeding when fresh platelet products are
not available.
cell separator machines in physician‐based medicine is
plateletpheresis, canine plateletpheresis has been rarely
reported and remains an underutilized resource in the Conclusion
clinical veterinary setting. Callan et al. used a Terumo
COBE Spectra machine to assess the safety and feasibil- Although cell separator machines are used daily in physi-
ity of plateletpheresis using 14 normal adult dogs. In all cian‐based medicine to treat a wide variety of diseases,
6
cases, a high‐quality, leukoreduced (<1 × 10 WBCs) their use in veterinary‐based medicine remains largely
11
platelet concentrate (mean total yield of 3.3 × 10 unexplored. Recent studies show that dogs can tolerate
platelets) was collected in a mean procedure time of only apheresis using human cell separator machines and that
105 min. Since citrate‐induced hypocalcemia was noted specific blood components can be harvested in a clinical
in some dogs, prophylactic IV Ca supplementation was veterinary setting. Moreover, it is clear that animals with
recommended. Appleman et al. then extended this work a variety of diseases, including cancer, can achieve posi-
by examining the effects of platelet in vitro function and tive clinical outcomes when treated with cell separator
in vivo survival using two different methods of cryo- harvest products. As such, apheresis in veterinary medi-
preservation (6% DMSO or Thrombosol). Although cine remains a largely untapped resource that should
cryopreserved platelets using either method were not expand in the future as more veterinarians become aware
able to mimic fresh platelets in terms of in vivo platelet of the technology and more machines become available
recovery, the authors concluded that both cryopreserved to our profession.

Further Reading

Appleman EH, Sachais BS, Patel R, et al. Cryopreservation Lupu M, Sullivan EW, Westfall TE, et al. Use of
of canine platelets. J Vet Intern Med 2009; 23: 138–45. multigeneration‐family molecular dog leukocyte antigen
Bartges JW, Klausner JS, Bostwick EF, et al. Clinical typing to select a hematopoietic cell transplant donor
remission following plasmapheresis and corticosteroid for a dog with T‐cell lymphoma. J Am Vet Med Assoc
treatment in a dog with acquired myasthenia gravis. 2006; 5: 728–32.
J Am Vet Med Assoc 1990; 196: 1276–8. Matus RE, Leifer CE, Gordon BR, et al. Plasmapheresis and
Callan MB, Appleman EH, Shofer FS, et al. Clinical and chemotherapy of hyperviscosity syndrome associated
clinicopathologic effects of platelepheresis on healthy with monoclonal gammopathy in the dog. J Am Vet Med
donor dogs. Transfusion 2008; 48: 2214–21. Assoc 1983; 183: 215–18.
Crump KL, Seshadri R. Use of therapeutic plasmapheresis Matus RE, Scott RC, Saal C, et al. Plasmapheresis‐
in a case of canine immune‐mediated hemolytic anemia. immunoabsorption for treatment of systemic lupus
J Vet Emerg Crit Care 2009; 19: 375–80. erythematosus in a dog. 1983. J Am Vet Med Assoc 1983;
Feige K, Ehrat FB, Kastner SBR, et al. Automated 182: 499–502.
plasmapoheresis compared with other plasma collection Matus RE, Gordon BR, Leifer CE, et al. Plasmapheresis in
methods in the horse. J Vet Med A 2003; 50: 185–9. five dogs with systemic immune‐mediated disease. J Am
Feige K, Ehrat FB, Kastner SBR, et al. The effects of Vet Med Assoc 1985; 187: 595–9.
automated plasmapheresis on clinical, haematilogical, Matus RE, Schrader LA, Leifer CE, et al. Plasmapheresis as
biochemical and coagulation variables in horses. Vet J adjuvant therapy for autoimmune hemolytic anemia in
2005; 169: 102–7. two dogs. J Am Vet Med Assoc 1985; 186: 691–3.